Development and Validation of a TP53-associated Immune Prognostic Model for Hepatocellular Carcinoma

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2019 Mar 20

PMID 30885723

Citations 203

Authors

Junyu Long

Anqiang Wang

Yi Bai

Jianzhen Lin

Xu Yang

Dongxu Wang

Xiaobo Yang

Yan Jiang

Haitao Zhao

Affiliations

Soon will be listed here.

Abstract

Background: TP53 mutation is the most common mutation in hepatocellular carcinoma (HCC), and it affects the progression and prognosis of HCC. We investigated how TP53 mutation regulates the HCC immunophenotype and thus affects the prognosis of HCC.

Methods: We investigated TP53 mutation status and RNA expression in different populations and platforms and developed an immune prognostic model (IPM) based on immune-related genes that were differentially expressed between TP53 and TP53 HCC samples. Then, the influence of the IPM on the immune microenvironment in HCC was comprehensively analysed.

Findings: TP53 mutation resulted in the downregulation of the immune response in HCC. Thirty-seven of the 312 immune response-related genes were differentially expressed based on TP53 mutation status. An IPM was established and validated based on 865 patients with HCC to differentiate patients with a low or high risk of poor survival. A nomogram was also established for clinical application. Functional enrichment analysis showed that the humoral immune response and immune system diseases pathway represented the major function and pathway, respectively, related to the IPM genes. Moreover, we found that the patients in the high-risk group had higher fractions of T cells follicular helper, T cells regulatory (Tregs) and macrophages M0 and presented higher expression of CTLA-4, PD-1 and TIM-3 than the low-risk group.

Interpretation: TP53 mutation is strongly related to the immune microenvironment in HCC. Our IPM, which is sensitive to TP53 mutation status, may have important implications for identifying subgroups of HCC patients with low or high risk of unfavourable survival. FUND: This work was supported by the International Science and Technology Cooperation Projects (2016YFE0107100), the Capital Special Research Project for Health Development (2014-2-4012), the Beijing Natural Science Foundation (L172055 and 7192158), the National Ten Thousand Talent Program, the Fundamental Research Funds for the Central Universities (3332018032), and the CAMS Innovation Fund for Medical Science (CIFMS) (2017-I2M-4-003 and 2018-I2M-3-001).

Citing Articles

Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma.

Yuan L, Yue Z, Ma Q, Zhang P, Xiao F, Chen L Front Immunol. 2025; 16:1528853.

PMID: 40051634 PMC: 11882876. DOI: 10.3389/fimmu.2025.1528853.

NALCN expression is down-regulated and associated with immune infiltration in gastric cancer.

Li X, Wu N, Wang C, Pei B, Ma X, Xie J Front Immunol. 2025; 16:1512107.

PMID: 40013144 PMC: 11860897. DOI: 10.3389/fimmu.2025.1512107.

Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells.

Cai P, Sun H, Jiang T, Li H, Huang D, Hao X Cancer Immunol Immunother. 2025; 74(4):114.

PMID: 39998561 PMC: 11861500. DOI: 10.1007/s00262-025-03960-1.

Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma.

He Q, Xiong Y, Yang X, Yu Y, Chen Z Discov Oncol. 2025; 16(1):197.

PMID: 39961903 PMC: 11832877. DOI: 10.1007/s12672-025-01955-z.

Precision oncology through next generation sequencing in hepatocellular carcinoma.

Shinde S, Bigogno C, Simmons A, Kathuria N, Ghose A, Apte V Heliyon. 2025; 11(3):e42054.

PMID: 39927143 PMC: 11804570. DOI: 10.1016/j.heliyon.2025.e42054.

References

Park N, Chung Y, Youn K, Song B, Yang S, Kim J . Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001; 33(5):397-401. DOI: 10.1097/00004836-200111000-00011. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View

Gui J, Li H . Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005; 21(13):3001-8. DOI: 10.1093/bioinformatics/bti422. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

Lai P, Chi T, Chen G . Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis. 2006; 12(2):387-93. DOI: 10.1007/s10495-006-0571-1. View

Petitjean A, Achatz M, Borresen-Dale A, Hainaut P, Olivier M . TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26(15):2157-65. DOI: 10.1038/sj.onc.1210302. View

Ho C, Liao W, Wang C, Lu Y, Huang H, Chen H . TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 2007; 177(7):763-70. DOI: 10.1164/rccm.200704-641OC. View

10.

Tanaka S, Arii S, Yasen M, Mogushi K, Su N, Zhao C . Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008; 95(5):611-9. DOI: 10.1002/bjs.6011. View

11.

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View

12.

Atta M, El-Masry S, Abdel-Hameed M, Baiomy H, Ramadan N . Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. Clin Biochem. 2008; 41(14-15):1131-9. DOI: 10.1016/j.clinbiochem.2008.06.006. View

13.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

14.

Tsai M, Tseng H, Liu C, Chang C, Tsai C, Tsou Y . Interaction of Exo1 genotypes and smoking habit in oral cancer in Taiwan. Oral Oncol. 2009; 45(9):e90-4. DOI: 10.1016/j.oraloncology.2009.03.011. View

15.

Brosh R, Rotter V . When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9(10):701-13. DOI: 10.1038/nrc2693. View

16.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

17.

Stratton M . Exploring the genomes of cancer cells: progress and promise. Science. 2011; 331(6024):1553-8. DOI: 10.1126/science.1204040. View

18.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

19.

Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S . KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011; 39(Web Server issue):W316-22. PMC: 3125809. DOI: 10.1093/nar/gkr483. View

20.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View